US-based Vedanta Biosciences has collaborated with Stanford University School of Medicine and Leiden University Medical Center to study food allergies in children and patients with C difficile infection or graft-versus-host disease, respectively.
Both collaborations are aimed at understanding patterns in the microbiome that may potentially inform clinical responses to therapy.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Under the agreement with Stanford, Vedanta will partner with the university’s director at Sean N Parker Center for Allergy and Asthma Research, Kari Nadeau to evaluate the potential connection between the gut microbiome and responses to oral immunotherapies in children with allergies.
Vedanta Biosciences chief scientific officer Bruce Roberts said: “We’re excited to announce our relationships with Stanford and Leiden University.
“Collaborations with leading academic centres are an important part of our strategy to support our drug development efforts with human data and with careful science.”
By teaming up with Leiden University, the company will generate clinical data from interventional studies of faecal transplantation in C difficile patients treated with donors from the Netherlands Donor Faeces Bank.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataClinical data will also be obtained from patients with graft-versus-host disease, in collaboration with Leiden University medical microbiology professor Ed Kuijper.
The data will be used for the discovery, development, and GMP manufacturing of rationally designed bacterial consortia drugs.
Vedanta Biosciences was founded by PureTech Health and a group of experts in immunology and microbiology, and is engaged in the microbiome field with capabilities to discover, develop and manufacture drugs based on live bacterial consortia.
